sanggenone-c and Liver-Neoplasms

sanggenone-c has been researched along with Liver-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for sanggenone-c and Liver-Neoplasms

Article	Year
Development of Novel Triazolo-Thiadiazoles from Heterogeneous "Green" Catalysis as Protein Tyrosine Phosphatase 1B Inhibitors. Scientific reports, 2015, Sep-21, Volume: 5 Condensed-bicyclic triazolo-thiadiazoles were synthesized via an efficient "green" catalyst strategy and identified as effective inhibitors of PTP1B in vitro. The lead compound, 6-(2-benzylphenyl)-3-phenyl-[1,2,4]triazolo[3][1,3,4]thiadiazole (BPTT) was most effective against human hepatoma cells, inhibits cell invasion, and decreases neovasculature in HUVEC and also tumor volume in EAT mouse models. This report describes an experimentally unidentified class of condensed-bicyclic triazolo-thiadiazoles targeting PTP1B and its analogs could be the therapeutic drug-seeds. Topics: Animals; Antineoplastic Agents; Benzofurans; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Movement; Chromones; Cyclin D1; Disease Models, Animal; Dose-Response Relationship, Drug; Female; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Models, Molecular; Neoplasm Invasiveness; Neovascularization, Pathologic; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; STAT3 Transcription Factor; Structure-Activity Relationship; Survivin; Thiadiazoles; Triazoles	2015

Article

Year

Development of Novel Triazolo-Thiadiazoles from Heterogeneous "Green" Catalysis as Protein Tyrosine Phosphatase 1B Inhibitors.

Scientific reports, 2015, Sep-21, Volume: 5

Condensed-bicyclic triazolo-thiadiazoles were synthesized via an efficient "green" catalyst strategy and identified as effective inhibitors of PTP1B in vitro. The lead compound, 6-(2-benzylphenyl)-3-phenyl-[1,2,4]triazolo[3][1,3,4]thiadiazole (BPTT) was most effective against human hepatoma cells, inhibits cell invasion, and decreases neovasculature in HUVEC and also tumor volume in EAT mouse models. This report describes an experimentally unidentified class of condensed-bicyclic triazolo-thiadiazoles targeting PTP1B and its analogs could be the therapeutic drug-seeds.

Topics: Animals; Antineoplastic Agents; Benzofurans; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Movement; Chromones; Cyclin D1; Disease Models, Animal; Dose-Response Relationship, Drug; Female; G1 Phase Cell Cycle Checkpoints; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Models, Molecular; Neoplasm Invasiveness; Neovascularization, Pathologic; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; STAT3 Transcription Factor; Structure-Activity Relationship; Survivin; Thiadiazoles; Triazoles

2015